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Abstract
Malaria continues to be the most lethal protozoan disease of humans. Drug development programs exhibit a high attrition
rate and parasite resistance to chemotherapeutic drugs exacerbates the problem. Strategies that limit the development of
resistance and minimize host side-effects are therefore of major importance. In this study, a novel approach, termed
evolutionary patterning (EP), was used to identify suitable drug target sites that would minimize the emergence of parasite
resistance. EP uses the ratio of non-synonymous to synonymous substitutions (v) to assess the patterns of evolutionary
change at individual codons in a gene and to identify codons under the most intense purifying selection (v#0.1). The
extreme evolutionary pressure to maintain these residues implies that resistance mutations are highly unlikely to develop,
which makes them attractive chemotherapeutic targets. Method validation included a demonstration that none of the
residues providing pyrimethamine resistance in the Plasmodium falciparum dihydrofolate reductase enzyme were under
extreme purifying selection. To illustrate the EP approach, the putative P. falciparum glycerol kinase (PfGK) was used as an
example. The gene was cloned and the recombinant protein was active in vitro, verifying the database annotation. Parasite
and human GK gene sequences were analyzed separately as part of protozoan and metazoan clades, respectively, and key
differences in the evolutionary patterns of the two molecules were identified. Potential drug target sites containing residues
under extreme evolutionary constraints were selected. Structural modeling was used to evaluate the functional importance
and drug accessibility of these sites, which narrowed down the number of candidates. The strategy of evolutionary
patterning and refinement with structural modeling addresses the problem of targeting sites to minimize the development
of drug resistance. This represents a significant advance for drug discovery programs in malaria and other infectious
diseases.
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Introduction
Malaria continues to be one of the most devastating human
infectious diseases. Plasmodium falciparum, which causes the most
virulent form of malaria, is responsible for 1 to 2 million deaths
annually, mostly in children under the age of 5 years in
predominantly resource-poor countries [1]. One of the major
concerns in malaria research is the dire need for novel therapeutic
strategies and the associated problem of parasite resistance.
Generally, the drug discovery pipeline is one of attrition and less
than one in every 50 potential projects proceed beyond the stage of
clinical trials, which emphasizes the importance of appropriate
drug target and lead compound selection [2]. Exacerbating this
problem is the ever-present danger that resistance may develop,
which in some cases may be rapid. The most dramatic example of
this in the case of malaria was the emergence of resistance to
pyrimethamine-sulfadoxine combination therapy in the 1960s,
which occurred within 12 months of introducing the drug [3].
Pyrimethamine targets the dihydrofolate reductase (DHFR)
enzyme in P. falciparum and DNA sequence analysis has identified
five common point mutations in the gene that confer resistance
[4]. Insights, therefore, that facilitate drug design and diminish the
likelihood of drug resistance in the parasite would be invaluable.
A number of bioinformatic approaches may be used to identify
essential amino acids in potential drug targets. The most
commonly employed methods such as PSI-BLAST [5] and hidden
Markov models [6], rely on protein sequence homologies and have
been used to detect conserved local sequence motifs. Another
approach that makes use of protein multiple sequence alignments
(MSAs) is the evolutionary tracing (ET) method [7]. ET is based
on the hypothesis that architecture-defining residues are mostly
invariant, and traces these residues through a phylogenetic tree to
guide investigators to structurally relevant sites. The protein
homology-based methods are limited however, since some
functional regions involve large contact areas that may only be
apparent from 3D protein structures and are not obvious from
primary sequence alignments [8]. Functional regions can also be
organism-specific, particularly if the sequence homologies are low,
and may not be clear from protein MSAs [9].
Homology methods do not include the evolutionary information
available from nucleic acid sequences. Following the rapid progress
in the field of molecular evolution and the vast amounts of genome
PLoS ONE | www.plosone.org 1 November 2008 | Volume 3 | Issue 11 | e3685sequence data available, it has been acknowledged that alternative
approaches, such as those which make use of evolutionary analyses,
shouldbeappliedatvariouspointsinthe drugdevelopmentpipeline
[10–12]. This is particularly appropriate for pathogen drug design
programs since whole genome data from several parasites (such as
the Plasmodium and related apicomplexa genomes) are now
available. To exploit this additional tier of information, pharmaco-
phylogenomic analyses of genes and whole genome have been
developed. Pharmacophylogenomics includes several evolutionary
considerations that are important in drug target selection [10] such
as: (i) orthologs versus paralogs, (ii) evolutionary dynamics of
lineages and whole genes, and (iii) selection pressures that lead to
rapid changes within genes. Differences in selective constraints
between humans and animal models are also important for drug
trials, where the drug target may be under different evolutionary
dynamics in the animal model [10,13].
In this study, we developed a novel approach, termed
‘‘evolutionary patterning’’ (EP), which makes use of the pattern
of evolutionary change at individual codons across coding
sequences to limit drug resistance by identifying the most
constrained sites. EP can be combined with structural information
and, like ET, is generic in nature. Nucleotide sequences contain
information about the rate of evolution, which can be measured to
determine the intensity of the selective force acting at a particular
site in a protein. If a particular residue is critical to the structure or
function of a protein, natural selection will remove any changes
that occur at that site (purifying selection) at a rate that reflects its
relative importance. These changes produce a pattern of evolution
in extant taxa and can be used to identify residues under extreme
purifying selection, which will potentially make the best drug
target sites. Since evolutionary pressures act to maintain the most
critical residues, it follows that mutations that confer drug
resistance are unlikely to evolve at these sites.
P. falciparum glycerol kinase (PfGK) was selected as a model
protein to evaluate the method. Glycerol kinase (GK) catalyzes the
ATP-dependant phosphorylation of glycerol to glycerol-3-phos-
phate [14], a pivotal metabolite with multiple roles of providing the
carbon backbone for glycerophospholipid synthesis, glycolysis or
gluconeogenesis, and transporting reducing equivalents from the
cytosol to the mitochondria for oxidative phosphorylation [14,15].
A putative GK has been annotated in the P. falciparum genome
database (PlasmoDB accession number PF13_0269). PfGK
potentially phosphorylates glycerol, which enters the parasite from
the host plasma via a P. falciparum aquaglyceroporin glycerol
facilitator [16,17]. Even though PfGK has not yet been validated
as a drug target, this is not a prerequisite for testing our approach.
PfGK fulfills many of the criteria that need to be considered when
planning a drug discovery program [18]. Importantly it provides
the essential backbone for phospholipid synthesis, which is
required for membrane biogenesis during the extensive prolifer-
ation of asexual intraerythrocytic stage parasites [19]. Disruption
of phospholipid synthesis impaired parasite development and
cleared malaria infection in mice and monkeys [20], providing
evidence for the essential role of GK in parasite metabolism. In
addition, expression of the PfGK gene is upregulated in response
to starvation and during gametocytogenesis when alternative
carbon sources are required [21].
Other aspects that make PfGK an attractive potential drug
target are that there are no known enzyme isoforms in the parasite
and that human GK (HsGK) is not present in erythrocytes.
Inhibitors such as 1-thioglycerol [22] and 59-adenylyl imidodipho-
sphate [23] are available, which reflects the potential of the
enzyme as a drug target. The crystal structure of an Escherichia coli
ortholog (EcGK) has been resolved [24] and a putative 3D model
of PfGK exists in the PlasmoDB database, which facilitates in silico
structural analysis and drug design. In addition, in this study we
provide the first evidence that PF13_0269 is indeed a GK
ortholog, since recombinant PfGK was functionally active and
phosphorylated glycerol in an in vitro assay.
The aim of this study was to investigate whether EP, together
with structural data, can be used to (i) identify drug target sites that
would limit the development of resistance and (ii) asses their
suitability, using PfGK as an example. Based on EP data, six
regions in PfGK were selected that contain residues under extreme
purifying selection that are different to the human enzyme and
thus represent potential drug target sites. Structural analysis
revealed their location in the 3D PfGK model, which provided
insight into the accessibility of drugs to these regions. It also
elucidated the relative importance of these sites in the function of
the enzyme. EP is a significant advance in the quest to identify
potential therapeutic target sites and will serve as an additional
filter to increase the likelihood of success of candidate proteins
entering the drug development pipeline.
Materials and Methods
Sequence data and multiple sequence alignments
(MSAs)
Twenty-eight orthologous GK protein and DNA coding
sequences, for which there is laboratory or bioinformatic evidence,
were retrieved from publicly accessible databases (Figure S1). True
orthologs were identified from a previous study [25] or from
pairwise alignments (data not shown). MAFFT [26] (algorithm G-
INS-i, blosum62 matrix, gap-opening penalty of 1.53 and gap-
extension penalty of 0.123) was used to perform the protein MSA
and alignment accuracy was confirmed with the HoT test [27].
Nucleic acid MSAs were performed with DAMBE [28] using the
protein sequence alignment as a template. BioEdit [29] was used
to remove insertions from the alignments. MSAs may be found in
Figures S2, S3, S4. In divergent nucleic acid sequences, saturation
(.1 substitution at the same site) may lead to incorrect results and,
where necessary, DAMBE was used to detect saturation.
Phylogenetic analysis
All phylogenetic analyses were performed with the PAUP* [30]
software package. Phylogenetic analyses were performed on (a) a
protein MSA of the 28 taxa, and (b) nucleic acid MSAs of major
branches within the group of 28 taxa. Nucleic acid sequences were
not used to construct a tree for the complete group of 28 taxa due
to sequence saturation. In each case, maximum parsimony and
maximum likelihood analyses were performed with 500 bootstrap
replicates, and the consensus tree was saved. For the maximum
likelihood phylogenetic tree construction the HKY85 evolutionary
model was selected based on model testing with MODELTEST
[31]. The branches within the group of 28 taxa that were analyzed
separately were: (i) the protozoa (12 taxa) and a subgroup of
protozoa, the Apicomplexa (8 taxa), and (ii) the metazoa (10 taxa)
and a subgroup of metazoa, the vertebrates (6 taxa). The taxa that
belong to each group or subgroup are shown in Figure 1.
Phylogenetic analysis of these individual groups was necessary for
further analysis with PAML and SLR (see below). TREEVIEW
[32] was used to view the trees.
Measurement of evolutionary change across GK coding
sequences
The ratio (v) of non-synonymous (dN) to synonymous (dS)
nucleotide substitutions is used as a measure of evolutionary
change and several methods exist to calculate these parameters,
Evolution and Drug Target Site
PLoS ONE | www.plosone.org 2 November 2008 | Volume 3 | Issue 11 | e3685each with their own strengths and weaknesses [33–35]. Three
categories of v are typically considered: i) v.1 reflects adaptive
change or positive selection, ii) v=1 implies neutral selection, and
iii) v,1 indicates stabilizing or purifying selection, where nucleic
acid substitutions that cause a change in the protein sequence
(non-synonymous substitutions) reduce organism fitness and are
removed by natural selection. Most genes exhibit a pattern of
purifying selection (,0.1,v,1.0), however, the intensity of
purifying selection varies between different genes [36], between
individual codons within a gene [37] and across individual lineages
within a tree [38]. Very small changes in v (for example, a
difference of 0.02) have biological relevance and, as expected, the
greatest intensity of purifying selection occurs as v approaches 0
[36]. Amino acid residues that are critical for protein structure and
function are expected to be coded for by codons that are under the
most intense purifying selection. To identify these codons, we
introduced a fourth category in this study, which we called
‘‘extreme purifying selection’’, and defined it as v#0.1. A value of
0.1 was chosen based on information from previous studies which
compared the intensity of purifying selection between groups of
genes [33,36]. PAML (PAML and SLR are described below) was
used to screen for codons with v,1.0, estimated with a Bayes
Empirical Bayes (BEB) probability of p.99%. To provide further
evidence for the degree of purifying selection, codons identified
with PAML were subjected to the site-wise likelihood ratio (SLR)
test. Codons with v#0.1 and a statistical significance of p,0.01,
adjusted for multiple comparisons, were placed in the ‘‘extreme
purifying selection’’ category. Codons for methionine (ATG) and
tryptophan (TGG) contain no potential synonymous substitutions
and were excluded from the analysis.
Evolutionary rate analysis with PAML and SLR
The PAML software package [39] (freely available at http://
abacus.gene.ucl.ac.uk/software/paml.html) uses a phylogenetic
analysis by maximum likelihood with several possible models to
analyze evolutionary rates. Four models analyzed with the codeml
algorithm were used: M0, M2, M7 and M8. M0 provided basic
phylogenetic information such as branch lengths and transition/
transversion ratios and allowed the consistency of these parameters
to be monitored. M2 identified codons in the three v categories
v.1.0, v=1.0 and v,1.0. M7 identified the likelihood of the
data fitting a b distribution with one v value. M8 complimented
M2, in that it was used to identify sites under positive selection (b
distribution and v.1.0). The probability of each codon fitting in a
particular v category (model M2) was determined by the BEB
probability estimate. Likelihood ratio tests to compare models
were unnecessary in this analysis.
The SLR method [40] combines the maximum likelihood
phylogenetic approach developed by Nielsen and Yang [41] with
the site-wise statistical test devised by Suzuki and Gojobori [42].
The SLR method determines v for individual codons with a
confidence interval for each v value given by a p value, adjusted
for multiple comparisons. The SLR software was kindly provided
by Tim Massingham from the European Bioinformatics Institute,
Hinxton Campus, United Kingdom.
PAML and SLR analysis were performed on the protozoa,
apicomplexa, metazoa and vertebrate groups using the phyloge-
netic trees generated above. Protozoan and metazoan taxa were
used to identify differences at individual codons in the GK coding
sequence along these two lineages. PfGK and HsGK coding
sequences were used as representatives of the protozoan and
metazoan branches, respectively. The apicomplexa and vertebrate
groups were used to observe the effects that changes to the number
of taxa and clades may have had on the data.
Identification of potential drug target sites in PfGK
By analyzing protozoan and metazoan clades separately, it was
possible to identify differences in codons that were under extreme
purifying selection in PfGK and HsGK. A pairwise alignment of
the two protein sequences was performed with the Needleman and
Wunsch algorithm [43].
Method validation
The EP approach was validated in two ways:
1. The P. falciparum dihydrofolate reductase (dhfr) region of the
dihydrofolate reductase-thymidylate synthase (dhfr-ts) fusion
gene (accession number PFD0830w) was analyzed with PAML
and SLR using the same Apicomplexa group (Figure 1) to
determine the v category of the codons in which point
mutations conferring resistance to pyrimethamine occurred. P.
yoelii was excluded from the analysis since dhfr and ts genes are
not fused in this species and the evolutionary pressures may
therefore be different. EP predicts that viable mutations are
unlikely to occur at codons under extreme purifying selection
and none of the five codons coding for the pyrimethamine-
resistant mutations (C50R, N51I, C59R, S108N, and I164L)
[3] were expected to have v#0.1 with a significant p value
(,0.01, adjusted for multiple comparisons).
2. The crystal structure of EcGK revealed 19 functionally
important amino acids [24] that are predicted to make contact
with glycerol, ADP and Mg
2+ ions. The 19 residues were
Figure 1. Phylogenetic reconstruction based on orthologous
glycerol kinase protein sequences. The unrooted radial tree was
generated using the maximum parsimony method. A maximum
likelihood tree demonstrated the same topology. Bootstrapping
provided .50% support for each node. The major branches comprising
the protozoa, metazoa, apicomplexa and vertebrates were analyzed to
identify differences in the patterns of sequence evolution between the
four groups.
doi:10.1371/journal.pone.0003685.g001
Evolution and Drug Target Site
PLoS ONE | www.plosone.org 3 November 2008 | Volume 3 | Issue 11 | e3685located in the EcGK sequence of the MSA used in the
phylogenetic analysis (Figure S2) and the corresponding PfGK
residues identified. These sites were expected to fall into the
extreme purifying selection category of v due to their
functional importance.
PfGK structure
A putative PfGK 3D structure, based on the EcGK crystal
structure, is available from the Plasmodium database version 5.4
(www.plasmodb.org/plasmo/home.jsp). Functionally important
residues and potential PfGK target sites were identified and
visualized using PyMOL v0.99 (www.pymol.org).
Parasite culture
FCR-3 P. falciparum parasites were cultured in vitro using fresh
human erythrocytes at 5% hematocrit and 10% AB plasma [44].
Cultures were incubated at 37uC in 93% N2,5 %C O 2 and 2% O2
(Afrox, South Africa).
Subcloning of the PfGK gene
P. falciparum DNA was extracted using phenol-chloroform and
ethanol precipitation [45]. The full length 1506bp PfGK gene was
amplified from 100ng DNA via PCR using 2.5U Expand High
Fidelity Taq polymerase (Roche, Germany) and a forward primer:
59-GATGGATCCATGAATGTCATATTAAGT-39 containing a
BamHI (underlined) restriction site and a reverse primer 59-
GATCTCGAGTTATAACTGTATTAATGT-39 containing a
XhoI (underlined) restriction site. PCR was performed under the
following conditions: 94uC, 2 min initial denaturation; 5 cycles:
94uC, 1 min; 35uC, 1 min; 72uC, 2 min; 30 cycles: 94uC, 1 min;
55uC, 1 min; 72uC, 2 min; and a final incubation at 72uC for
10 min. The amplified PfGK DNA sequence and pGEX-4T-2
(Amersham, UK) expression vector were digested with BamHI and
XhoI (Fermentas, Lithuania) and PfGK was ligated downstream of
the Glutathione S-transferase (GST) gene sequence in the vector.
Competent DH5a E. coli (Invitrogen, USA) were transformed with
the plasmid construct and positive colonies were selected on Luria
Bertani (LB) medium supplemented with 100 mg/ml ampicillin
(Roche, Germany). The PfGK insert was verified using gene
specific PCR, plasmid extraction, restriction enzyme analysis and
DNA sequencing.
Expression and purification of recombinant GST-PfGK
(rPfGK)
rPfGK was expressed in Rosetta2 (DE3) E. coli (Novagen, USA) as
a fusion protein with an N-terminal GST tag. Transformed cells were
selected in LB medium containing 100 mg/ml ampicillin and 50 mg/
ml chloramphenicol (Roche, Germany). 1/100 (v/v) culture was
added to LB and cells were allowed to grow to an OD600nm$0.6 at
37uC before induction with 1mM isopropyl thio-b-D-galactoside
(IPTG, Promega, USA) for 6 hours at 37uC. rPfGK was predom-
inantly expressed as insoluble protein trapped in inclusion bodies in
E. coli and was purified with BugBusterH HT (Novagen, USA) as per
manufacturer’s instructions. rPfGK was denatured in 6M guanidine
hydrochloride, 50mM Tris HCl pH 8.0, 100mM NaCl, 10mM
EDTA and 10mM DTT (Merck, USA) [46] at 4uC overnight. The
sample was diluted to 3M guanidine hydrochloride with refolding
buffer (200mM Tris-HCl pH 8.0, 10mM EDTA, 1M L-arginine,
0.1mM PMSF, 2mM reduced glutathione, 0.2mM oxidized
glutathione, Merck, USA). To refold the protein, it was dialyzed 8–
1 0t i m e si nm i n id i a ly s i st u b e s( Pi e r c e ,U S A )a g a i n s t1 0v o l u me so ft h e
buffer for 5 min at room temperature. The refolded GST-PfGK was
purified by affinity chromatography with GSTuMag
TM Agarose
beads (Promega, USA). Recombinant proteins were eluted from the
beads with 100mM reduced glutathione, 50mM Tris-HCl, pH 8.0
elution buffer.
To improve the expression of soluble protein, 1/100 (v/v) of the
antibiotic-selected cultures were added to either the Overnight
Express
TM Instant TB Medium (Novagen, USA) autoinduction
system and allowed to grow to an OD600nm$1.5 at room
temperature or added to LB medium without antibiotics, grown
to OD600nm$1.0 at 37uC and induced with 0.4mM IPTG at room
temperature to an OD600nm$1.5. Cells expressing rPfGK were
lysed with BugBusterH HT supplemented with the Protease
Inhibitor Cocktail Set III (Novagen, USA). rPfGK was purified
from the soluble E. coli protein fraction using GST#Mag
TM
Agarose beads as described above. Protein fractions were analysed
by SDS-PAGE [47] and immunoblotting with a 1:10000 (v/v)
diluted anti-GST HRP-conjugated antibody (Amersham Biosci-
ences, UK) and visualized with the SuperSignalH West Pico
Chemiluminescent Substrate (Pierce, USA).
PfGK Enzyme Activity
Purified rPfGK was quantitated using Coomassie Plus-the
Better Bradford
TM Assay kit (Pierce, USA). For the enzyme assay,
EcGK (Worthington, UK) was used as a positive control and
enzyme activity was measured in an ADP-coupled spectrophoto-
metric assay as per manufacturer’s instruction. Recombinant GST
was used as a negative control and the blank had no rPfGK.
Briefly, 0.5–1.0 mg purified rPfGK was added to a 3ml reaction
mixture containing 0.7ml reagent solution (8.5mM disodium ATP,
1.22mM NADH, 2mM phosphoenolpyruvate, 28mM MgSO4,
26mM reduced glutathione, 5units pyruvate kinase, 10units lactate
dehydrogenase, pH 7.4, Roche, Germany), 2.1ml carbonate-
glycine buffer (0.4M glycine, pH 8.9, 45mM potassium carbonate,
Roche, Germany) and 0.1ml 0.1M glycerol (Fluka, USA). Enzyme
activity was detected as a decrease in NADH absorbance at




trees generated from the GK protein sequences of the 28 taxa
demonstrated the same topologies (Figure 1). They were consistent
with previous data [48] and the sequences were therefore suitable
for further analysis. Nucleic acid sequence phylogenetic trees of the
protozoan, metazoan, apicomplexa and vertebrate branches were
used in the PAML and SLR analyses. Figures S5 and S6 containthe
protozoan and metazoan phylograms, respectively. A logged output
of the PAUP* data for generating phylogenetic trees for the
protozoan branch is supplied as an example (Figure S7) and
provides information regarding the g1 statistic, number of
informative characters (parsimony analysis), treatment of gaps,
heuristic search settings, distance matrices, tree statistics, tree
lengths and bootstrap support.
Evolutionary patterns for P. falciparum and human GK
The PAML and SLR data were combined for the protozoan and
metazoan clades to show a plot of the BEB posterior probability
estimate for each category of v across PfGK (protozoan) and HsGK
(metazoan) coding sequences (Figure 2). For categories v.1.0,
v=1.0 and 0.1,v,1.0 the PAML data were used. A summary of
the PfGK data generated from the four models implemented with
PAML is given in Table 1. The category v#0.1 was defined by the
combined PAML and SLR data. PAML (Model M2) identified
nearly 300 codons with v,1.0 and a BEB probability estimate of
Evolution and Drug Target Site
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identified 93 codons with v#0.1 and an adjusted p value ,0.01
(SLR outputs can be found in Figures S8 (protozoa) and S9
(metazoa)). The 93 codons are represented in Figure 2 by the extreme
purifying selection category with a BEB probability estimate of 100%
(blue lines) and were used as a guide to select possibledrug target sites.
For both PfGK and HsGK, codons in the extreme purifying selection
category spanned the entire coding sequence, although the 5 ` and 3 `
ends were significantly less conserved overall, and this was also more
pronounced in PfGK. PAML and SLR analyses of the apicomplexa
and vertebrate subgroups resulted in slightly more codons being
placed in the extreme purifying selection category (112 in the
apicomplexa and 121 in the vertebrate clades as opposed to 93 in the
protozoan and 97 in the metazoan clades). Most of the additional
codons were labeled as ‘‘constant’’ in the SLR analysis, indicating
that the codons were identical across taxa.
PAML (Model M2) also identified 21 sites (Figure 2 and Table 1)
under neutral (red lines) or positive (yellow lines) selection (v$1)
although these were not statistically significant at the 99% level.
The reason for this may be that the natural selective forces are
weak or there may be too little evolutionary information present in
the available sequences to make the findings significant. The lack
of conservation at neutral or positively selected codons indicates
that these sites are unlikely to be critical for GK function. Drugs
targeted against these residues may therefore fail to disrupt
enzyme activity, and even if they did, mutations conferring
resistance are likely to evolve.
Some residues in PfGK under extreme purifying selection were
not part of any recognized functional domains (Figure 3).
However, these may be important in protein folding or play a
role in the stability of the 3D molecular structure. In addition,
some residues in this category were not classified as such in HsGK,
and vice versa. The reason for this is most likely the differing
selection pressures acting on the two proteins.
Validation of the EP approach
1. The SLR logged output following analysis of the edited MSA of
orthologous dhfr coding sequences is available in Figure S10.
Figure 2. Posterior probabilities for four categories of v across GK coding sequences. The Bayes Empirical Bayes posterior probability
estimates (BEB) determined from the PAML analysis of the protozoan and metazoan clades were plotted for each category of v across the P.
falciparum (PfGK) and human (HsGK) GK coding sequences, respectively. Residues under extreme purifying selection (blue lines) are potential drug
target sites. Categories for v are indicated with colored bars: yellow (v.1.0, positive selection), red (v=1.0, neutral selection), white (0.1,v,1.0,
purifying selection), and blue (v#0.1, extreme purifying selection). The v,0.1 category was defined by combining PAML (BEB.99%) and SLR
(p,0.01) data.
doi:10.1371/journal.pone.0003685.g002
Table 1. Parameter estimates, log-likelihood values and selective pressures across codons for P. falciparum glycerol kinase under
models of variable v ratios.
Model v categories , k Parameters Neutral/positively selected sites
M0 1 24568.9 1.8 v=0.028 None
M2 3 24543.5 2.0 v=0.02 (p=0.95), v=1.0 (p=0.04),
v.1.0 (p=0.00)
N2 V16 E22 I25 S28 T52 N56 I70 K71 K76 I92 P149 E226 L236
N237 E277 S331 E373 V407 D461 K492
M7 b distribution 24520.8 1.9 p=0.30708, q=7.68249 Not allowed
M8 b distribution, v.1.0 24520.8 1.9 p=0.30708, q=7.68255 and v.1.0
(p=0.00)
None
Models were implemented with the codeml algorithm in the PAML package. Under the M2 model, there were .300 codons with v,1.0 and a posterior probability of
.99% (not listed in table). These were subjected to the SLR test for further categorization of the intensity of purifying selection (see text). There were 21 neutral or
positively selected sites (v$1) with a Bayes Empirical Bayes (BEB) posterior probability of .50%, although none of these were statistically significant at 95%. Under the
M8 model, no statistically significant positively selected sites were identified. For M7 and M8, p and q are the shape parameters of the b distribution. ,=log-likelihood
estimate, k=transition/transversion ratio, p=BEB posterior probability. Numbering corresponds to the sequence alignment in Figure 3.
doi:10.1371/journal.pone.0003685.t001
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the key mutation S108N that confers drug resistance was that
of weak purifying selection with an adjusted p value that was
not statistically significant. The remaining four codons
implicated in drug resistance either had no synonymous
substitutions (codon 45) or were not significantly different from
a random alignment (codons 46, 54, and 159), implying that
they are either under weak purifying, neutral or positive
selection. As predicted by EP, none of the five codons that
mutated to provide resistance against pyrimethamine in
PfDHFR were under extreme purifying selection.
2. Twelve of the 19 functionally important residues that are
invariant in GK and which had been included in the MSA
(Figure S2) were categorized as being under extreme purifying
selection (Figure 3). This was taken as further validation of the
EP approach. The remaining seven functional residues did not
fall into the extreme purifying selection category for the
following reasons: (i) W103 (glycerol binding) and M414 (ADP-
binding) were excluded since there is only one possible codon
for each, and (ii) residues K15, V315, S316, S328 and N417 (all
ADP-binding) are variable in a MSA [49], indicating that non-
synonymous substitutions are present in the coding sequences,
which are therefore, highly unlikely to be under extreme
purifying selection. The variability in these four ADP-binding
sites may relate to the fact that the ADP-binding pocket is
formed by 12 amino acids and that not all of these are critical.
Selection of potential drug target sites
For the purposes of limiting resistance and providing an
adequate target site, regions containing several amino acids under
extreme purifying selection would be ideal. Examples of such
regions in PfGK are residues 82–86 (QRETV), 99–102 (NAIV),
244–247 (GDQQ), 266–270 (GTGVF) and 345–349 (FVPAF)
(Figure 3). However, most of these amino acids are identical in
HsGK and these sites were therefore not selected. Other regions
were chosen using the following criteria: (i) they contained one or
more residues with v#0.1, (ii) the remaining residues had low v
values (,0.2), and (iii) PfGK and HsGK shared no more than two
identical residues. The exact length of the region would depend on
its potential druggability, an analysis of which is beyond the scope
of this paper, but for demonstration purposes an arbitrary length
of five residues was used. For example, in region I in PfGK, I7 and
D8 are under extreme purifying selection. D8 binds Mg
2+ and is
the same in HsGK, but I7 aligns with V in the human sequence.
Residues flanking the amino acids under extreme purifying
selection were examined and the region was extended by three
residues (v values #0.14) towards the N-terminus. Six regions
(labeled I to VI) were selected that may be useful as potential drug
target sites (Figure 3, Table 2).
Structural analysis
GK is a member of the ATPase superfamily that shares a
common ßßßaßaßa tertiary fold domain [50]. Under physiolog-
Figure 3. Multiple sequence alignment of PfGK, HsGK and EcGK. To identify differences in selective constraints, PfGK and HsGK were
analyzed separately, as part of protozoan and metazoan clades, respectively, and compared. Residues under extreme purifying selection are
highlighted in yellow in PfGK and are in brown font in HsGK. Residues highlighted in gray in PfGK are under neutral or positive selection. Sites that
bind glycerol (green circle), ADP (blue star) and magnesium (red triangle) were determined from the crystal structure of EcGK [24]. Corresponding
residues in PfGK were determined form the MSA. Residues are numbered according to the PfGK sequence. Potential drug target sites are indicated
(red bar) and labeled with Roman numerals. Underlined regions in EcGK are implicated as follows: intersubunit interactions (black), FBP regulatory site
(green) and IIA
Glc regulatory site (orange).
doi:10.1371/journal.pone.0003685.g003
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equilibrium, as well as inactive tetramers, each composed of
identical monomers [51]. Each monomer (Figure 4A) consists of
two major domains separated by a deep active site cleft and
contains six subdomains involved in the ATPase core (light green),
intersubunit interactions (aquamarine) and substrate binding (red).
EcGK is independently and non-competitively inhibited by two
allosteric effectors: the glycolytic intermediate fructose 1,6-bispho-
sphate (FBP) and IIA
GLC, a component of the E. coli phosphoe-
nolpyruvate:glycose phosphotransferase system [24].
A putative PfGK structural model indicating functionally
important residues based on homology to EcGK is shown in
Figure 4B. To evaluate the functional significance of the six
potential drug target sites, the regions were mapped to the PfGK
structure (Figures 4C and 4D). All the regions, except for Region
II, were found in functionally important domains as summarized
in Table 2.
Region I (magenta) represents a b sheet at the N-terminus of
PfGK and is located within the catalytic cleft. It shares a common
Mg
2+ binding site (D8) with HsGK. Region II (red) has two
negatively charged residues and represents a loop structure
between an a helix and b sheet at the surface of the molecule. It
does not represent any known functional or structural GK
domain. Region III (black) forms an a helix-turn-b sheet structure
and is located within the hydrophobic core of the molecule, below
the glycerol-binding domain. It represents part of the ATPase core
in Domain I. Region IV (blue) is part of a loop between two a
helices and is located at the entrance to the catalytic cleft. S328
participates in ADP-binding and the adjacent P327 may confer
conformational stability to the ADP-binding site. Region V
(orange) represents a loop structure on the surface of the molecule
and contains residues involved in intersubunit interactions in
EcGK dimerization. Region VI (green) is situated on an a helix
and is the site for EcGK IIA
GLC-allosteric regulation. In PfGK,
Region VI forms part of a low complexity region which loops out
on the surface of the molecule. All five residues within Region VI
are positively charged and share no similarity with the corre-
sponding region of HsGK, which has three negatively charged
residues.
Recombinant PfGK is active
The expressed rPfGK protein was predominantly insoluble and
trapped as inclusion bodies in E. coli (Lane 3, Figure 5A).
Refolding and purification of rPfGK from the inclusion bodies
yielded inactive enzyme (data not shown). Expression of soluble
rPfGK was improved to produce ,100ng purified rPfGK from a
100ml culture (lane 4, Figure 5A). The rPfGK protein migrated at
,72kDa on a polyacrylamide gel and immunoblot analysis
(Figure 5B) confirmed the presence of the GST tag on rPfGK.
Enzyme assays from three independent purifications showed that
rPfGK was active and phosphorylated glycerol (Figure 5C).
Discussion
Evolutionary-based approaches for the identification of struc-
turally and functionally important residues in protein sequences
have focused on sequence homology, phylogenetic tracing of
structurally-important residues (ET) and confirmation of orthology
(as opposed to paralogy). In addition, an analysis of evolutionary
rates has been suggested as a means to identify genes that are
subject to adaptive evolution and should therefore be avoided as
drug targets [10]. In this study a new approach, termed
evolutionary patterning (EP) was introduced with the aim of
identifying and assessing the suitability of potential drug target sites
from the point of view of limiting the evolution of mutations
conferring drug resistance. Furthermore, using PfGK as an
example, structural modeling was used to refine the selection of
potential target sites by assessing their functional and structural
significance. The putative PfGK was cloned and the recombinant
protein was active, verifying the database annotation and justifying
it as a potential target.
Validation for the EP approach was provided by PfDHFR data.
EP theory predicted that none of the codons that evolved
mutations providing resistance against pyrimethamine would be
under extreme purifying selection, and this was demonstrated in
this study. It is also interesting to note that none of the drug-
binding residues in the PfDHFR enzyme (I14, C15, D54, F58,
P113 and I164) [52] are under extreme purifying selection (data
not shown), and these residues would not have been selected as
drug target sites using the EP approach. As evident from the
PfDHFR example, future drug development programs that target
enzyme active sites without taking into account the evolutionary
dynamics run the risk of failure.
Potential drug target sites identified by EP and structural
mapping
Analysis of the evolutionary patterns of PfGK residues in
comparison to the human enzyme led to the selection of six
regions that included sites that are not prone to viable mutation.
Differences between HsGK and PfGK sequences were favored
when selecting potential drug target sites since this would,
theoretically, diminish drug side-effects. These sites were further
evaluated by structural modeling of PfGK. Of the six regions
identified, region IV (blue in Figures 4C and 4D) appears the most
Table 2. Summary of the location and function of potential PfGK drug target sites.
Region Color
1 Sequence Functional domain
2 Location Drug Target
I Magenta ILSID Mg
2+-binding Catalytic Cleft No
II Red IDDGT None Surface No
III Black
3 GNINT ATPase core Core No
IV Blue DDPSE ADP binding Catalytic Cleft Yes
V Orange NTTGV Subunit interaction Surface Yes
VI Green KKRKK Allosteric regulation Surface Yes
1Colors of each region correspond to those in Figures 4C and 4D.
2GK functional and regulatory domains are illustrated in Figures 4A (EcGK) and 4B (PfGK).
3This region is in the core of the molecule and cannot be seen on the surface model (Figure 4D).
doi:10.1371/journal.pone.0003685.t002
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drug target: (i) one residue (S328) has a predicted function (ADP-
binding) as determined from MSAs and the crystal structure of
EcGK [24], (ii) the target site is located at the entrance to the
catalytic pocket, (iii) D326, P327 and E329 are adjacent to the
S328 ADP-binding residue and are under extreme purifying
Figure 4. EcGK and PfGK models. Models A (EcGK) and B (PfGK) are displayed as ribbon structures with functional residues illustrated as sticks. (A)
An EcGK monomer with residues involved in binding to ADP (blue), Mg
2+ (yellow), glycerol (red), FBP (orange) and IIA
GLC (purple) [24,70]. Positions of
Domains I and II are labeled. a Helices and ß sheets within Domains I and II form the ATPase domain, shaded in light green and areas involved in
subunit interactions are shaded in aquamarine. (B) The PfGK model showing functional residues based on EcGK. (C) PfGK ribbon structure and (D)
surface model showing potential drug target sites. Residues within each region are summarized in Table 2 and are highlighted as follows: Region I
(magenta), Region II (red), Region III (black), Region IV (blue), Region V (orange) and Region VI (green). Region III is below Region I and is difficult to
visualize in the ribbon configuration (C) since it is partly obscured by one of the helices. It is within the core of the molecule and cannot be seen on
the surface PfGK model (D).
doi:10.1371/journal.pone.0003685.g004
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region are unlikely to develop, and (iv) three out of the five residues
in PfGK are different to the human enzyme, which, favors
selective targeting of the parasite.
Analysis of the other potential drug target sites revealed that
regions I, II and III may not be good candidates. Region I (magenta
in Figures 4C and 4D) binds Mg
2+ within the catalytic pocket. Its
location makes it an attractive target site, however, small Mg
2+ ions
can easily enter the catalytic pocket whereas a larger potential lead
compound may not be able to gain access. Region II (red in
Figure 4C and 4D) is on the surface of the molecule making it
accessible to a drug, however, it is relatively isolated from the
catalytic domain and is not involved in any functional interactions.
Targeting this site may therefore not inhibit the enzyme, although
the possibility of long range conformational changes induced by the
binding of a drug cannot be ruled out. Region III (black in
Figure 4C) is within the hydrophobic core of the molecule and may
be inaccessible to drugs.
Region V (orange in Figures 4C and 4D) and VI (green in
Figures 4C and 4D) are exposed on the surface of the molecule
and in EcGK, they participate in intersubunit and allosteric
interactions, respectively. The oligomeric state of the active PfGK
enzyme, as well as potential regulation by allosteric effectors, is not
known. However, regions V and VI are in close proximity to each
other and could collectively form one drug target site.
The structural modeling of PfGK illustrates how it complements
and refines the EP approach by eliminating sites that are not
useful. However, it should be noted that this type of analysis
represents an initial step, since the druggability of each site
requires evaluation by medicinal chemists [53,54].
EP: strengths and advantages
The fundamental strength of EP is that the intensity of purifying
selection on individual codons is measured and the most
evolutionary constrained amino acids are identified. Residues that
are under extreme purifying selection imply that mutations at
these sites dramatically decrease organism fitness and would be
removed by natural selection. Viable mutations leading to drug
resistance are therefore less likely to evolve, which will effectively
increase the lifespan of therapeutic agents targeted to these sites. In
addition, sites under positive or neutral selection are likely to adapt
to drug pressures and should be avoided as targets.
Quantifying the pattern and intensity of selection across codons
within a gene has additional advantages. For example, it is
important to know the v values of residues adjacent to amino acids
under extreme purifying selection if a particular region is
considered a potential drug target site. Furthermore, lead
compounds are unlikely to interact exclusively with a stretch of
contiguous amino acids. It is more likely that, due to protein
folding and subsequent 3D structure, a drug makes contact with
several non-contiguous residues. It would be important to identify
the selection pressure at these residues since amino acid changes at
these sites may dramatically affect drug binding. Information
gathered with EP is therefore valuable in the iterative process of
drug design: (i) appropriate targets sites are identified and selected,
(ii) lead compounds are designed to interact with the selected sites,
(iii) in silico docking identifies all the potential contact sites, (iv)
contact sites are evaluated with EP, (v) lead compounds are
modified if necessary such that contacts are not made with sites
that are prone to change, and (vi) the process may be repeated
until the drug-protein interactions are optimized or the potential
target site is abandoned.
The PAML and SLR methods can detect very small changes in
v at individual codons and in different lineages, which can be
statistically and biologically significant [36]. In this respect, EP can
be applied to subgroups delineated by branch points in a
phylogenetic tree to detect such differences. This is important
for the design of antiprotozoal drugs where differences between
host and parasite orthologs are exploited to target the parasite
selectively and minimize side-effects [55].
Genome-wide analyses of P. falciparum diversity has identified
vast numbers of SNPs (single nucleotide polymorphisms) located
throughout the genome [56,57]. This has raised concerns
regarding drug development since drugs targeted to polymorphic
Figure 5. rPfGK purification and enzyme activity. (A) SDS PAGE analysis and (B) immunoblot analysis showing the expression and affinity
purification of rPfGK from the soluble protein fraction of E. coli cells. Lane 1: total E. coli protein, Lane 2: soluble protein fraction, Lane 3: insoluble
protein fraction, Lane 4: purified rPfGK, Lane 5: red cell membrane marker. (C) The oxidation of NADH to NAD
+ in the glycerol kinase coupled enzyme
reaction measured at 340nm shows active rPfGK (green) compared to the blank (black), negative control GST (red) and the positive control EcGK
(blue).
doi:10.1371/journal.pone.0003685.g005
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However, the EP approach would overcome this problem since
polymorphic sites that lead to changes in amino acid residues will
not have v#0.1, and will therefore not be selected as potential
drug target sites.
Finally, to maximize the robustness for predicting target sites,
EP combines two statistical estimates of v. First, the maximum
likelihood codon substitution model developed by Yang and
Nielsen [58], which takes into account the transition/transversion
ratio and nucleotide usage bias, is used to determine the v
category (for example, v,1.0). The BEB probability estimate is
used as a measure of the accuracy of that inference and only
codons with v,1.0 and a probability estimate with a confidence
interval greater than 99% are selected (model M2 in the codeml
algorithm). Second, the sitewise test developed by Suzuki and
Gojobori [42] is used to perform a likelihood ratio test to identify
codons with v values significantly different from 1.0 with an
adjusted p,0.01 [40]. Codons with v#0.1 and which satisfy both
statistical criteria are investigated as potential drug target sites.
EP: limitations and potential pitfalls
EP is limited by the availability of adequate sequence data. A
discussion of the selection of an optimal data set is beyond the
scope of this paper and the reader is referred to Yang [59] for an
authoritative treatment of the topic. However, one aspect that
emerged from this study is that care must be taken when selecting
phylogenetic subgroups for the purpose of comparing host and
parasite proteins. Although PAML and SLR are designed to
account for phylogenetic parameters like branch lengths, we
investigated whether differences in the evolutionary relationships
between taxa in protozoan and metazoan clades might have
influenced the results. To do this, we used a subset of the taxa in
each of the two groups (apicomplexa for the protozoan clade and
vertebrates for the metazoan clade) and repeated the analyses,
which resulted in slightly more codons being placed in the extreme
purifying selection category. Most of the additional codons were
labeled as ‘‘constant’’ in the SLR analysis, indicating that the
codons were identical across taxa. This suggests that the reason for
the identification of more codons in the apicomplexa and
vertebrate clades was the result of using fewer taxa and smaller
evolutionary distances in the phylogenetic tree. The fact that there
were only minor differences is testament to the power of PAML
and SLR. Nevertheless, this does indicate that optimal input data
must be used, particularly in studies such as this one where small
differences in the evolutionary constraints of a protein are being
investigated.
Another possible limitation of EP is that some potential drug
target sites may be missed due to the rigorous statistical criteria
imposed by the method. However, when one considers the time
span of drug development pipelines, it seems more appropriate to
run the risk of missing potential sites rather than permitting the
inclusion of residues that are likely to mutate.
One issue that the current description of EP does not account
for is the possibility that drug resistance may develop in cases
where mutations at the drug target site are combined with
compensatory mutations elsewhere in the protein. However, this
problem can be addressed by investigating the potential co-
evolution between codons. Methods to measure correlated
evolutionary rates within a protein exist and may be incorporated
into an EP analysis [60]. In addition, EP cannot account for
heterotachy, a phenomenon that describes shifts in evolutionary
rates over time [61]. However, these changes occur over extended
evolutionary time periods and may therefore have a limited impact
on drug viability.
A potential pitfall of EP is that database sequences will typically
be used. Databases occasionally contain erroneous information [62]
and this possibility should be considered when results are not in
keeping with biological expectations. In the process of performing
this study, a number of annotation errors were detected, which
would have led to incorrect results. For example, to investigate the
consequences of inadvertently using a paralog, the chicken GK2
(NCBI accession number XP_416788.2) was included in the
analysis of the metazoan clade (data not shown). This greatly
diminished the number of codons under extreme purifying selection
(from 121 to 6) emphasizing that only true orthologs must be used,
which is in keeping with previous reports [10,13].
For the purposes of drug design, the temptation to screen for
potential target genes by applying evolutionary analyses to whole
coding sequences represents a serious potential pitfall. Estimating
v for a whole gene will provide misleading information since v
may vary considerably at individual codons. A recent demonstra-
tion of this is the MHC (major histocompatibility) gene, which
demonstrates an average v of weak purifying selection (0.6)
although the selective constraints on codons vary from positive
selection (v=4.7) to extreme purifying selection (v#0.1) [63].
EP: applications
EP is generic in nature and can potentially be applied to any set
of coding sequences, provided there are sufficient data to make the
results statistically meaningful. For drug development against the
malaria parasite, there is the additional advantage that approx-
imately ,60% of the predicted proteins in P. falciparum have little
or no homology to known proteins [64]. These proteins are
annotated as ‘‘hypothetical’’ in PlasmoDB and have orthologs in
other Plasmodium species, which may be used for comparison.
Applying EP in this context will identify residues under extreme
purifying selection in proteins with no human ortholog, which will
make them attractive drug targets.
EP analysis of PfGK demonstrated that many of the sites under
extreme purifying selection have functional or structural importance.
This finding suggests that EP may also be used to identify these
residues in uncharacterized ‘‘hypothetical’’proteins in P.falciparum,o r
indeed, any other organism. This potential application is currently
being investigated in our laboratory and represents a rapid, cost-
effective way of advancing our knowledge of these proteins. In the
absence of EP, the identification of structurally and functionally
important residues depends on crystal structures, analysis of protein-
protein interactions and site-directed mutagenesis.
It is envisaged that EP will be used as an initial step to identify
the most suitable drug target sites in a protein. This information
can subsequently be utilized by medicinal chemists further along
the drug development pipeline to initiate the design of appropriate
compounds.
Software available for EP analysis
A number of methods exist for estimating v [58,65,66] and
although PAML and SLR were used in this study, there are many
other excellent and equally suitable software packages. A
comprehensive list of the available software for analyses in
molecular evolution is maintained by the Department of Genome
Sciences, University of Washington, Seattle, USA and may be
found at http://evolution.genetics.washington.edu/phylip/soft-
ware.html. For most applications the maximum likelihood
framework appears to be as good or superior to other methods,
however, the accuracy of the estimation depends on a number of
factors such as the true v value and the transition/transversion
ratio [58], and alternative methods should be considered when
these parameters are unexpectedly high.
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netic clusters can also be identified and mapped to tertiary
structures with software like DIVERGE (Detecting Variability in
Evolutionary Rates among Genes) [67]. This enables the user to
identify sites that have different evolutionary, and therefore,
functional constraints in two branches within a tree (for example,
host and pathogen branches), thereby focusing on regions that are
specific to the pathogen cluster. Similarly, ‘‘tertiary windowing’’
allows the user to select structural regions of interest and asses the
evolutionary constraints at the chosen sites, which has the
advantage of examining the 3D structure of a protein in order
to select drug target sites prior to performing a comprehensive
evolutionary analysis [68]. DIVERGE, tertiary windowing and
related software will be particularly useful for selecting appropriate
sites by avoiding residues that are likely to change, however, the
ability to detect amino acid sites that are under the most extreme
purifying selection is limited.
A noteworthy point applicable to almost all methods is that
current evolutionary analysis makes the assumption that synony-
mous substitutions are neutral and therefore have no bearing on
the interpretation of v. Although this is not necessarily true [69],
the selective forces acting on synonymous changes are poorly
understood. Until such time that evolutionary models are
developed to account for this, the assumption of neutrality at
synonymous sites remains.
Conclusions
EP is a novel approach that makes use of the evolutionary
dynamics of genes and proteins for the purposes of selecting suitable
drug target sites. EP identifies amino acids that are under the most
extreme evolutionary constraints. These sites are predicted to be the
most appropriate drug targets since they are structurally and/or
functionally essential, and are the least likely to undergo viable
mutations, thereby limiting resistance and increasing the lifespan of
a drug. Although EP is applicable on its own, molecular modeling
compliments and refines the process of target site selection by
assessing the topography and functional significance of the potential
sites. EP, combined with structural analysis, addresses a major
obstacle to efficient drug design: that of appropriate target site
selection to limit the evolution of resistance. This approach may be
used as an inexpensive first-line strategy for supplying medicinal
chemists with potential drug target sites, which could significantly
reduce the attrition rate and lead to more effective therapeutic
agents against malaria and other infectious diseases.
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orthomcl.org/cgi-bin/OrthoMclWeb.cgi), and PlasmoDB version
5.3 (http://plasmodb.org).
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